153 related articles for article (PubMed ID: 18799312)
1. 6-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors.
Bromidge SM; Bertani B; Borriello M; Faedo S; Gordon LJ; Granci E; Hill M; Marshall HR; Stasi LP; Zucchelli V; Merlo G; Vesentini A; Watson JM; Zonzini L
Bioorg Med Chem Lett; 2008 Oct; 18(20):5653-6. PubMed ID: 18799312
[TBL] [Abstract][Full Text] [Related]
2. 8-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors--part II.
Bromidge SM; Bertani B; Borriello M; Bozzoli A; Faedo S; Gianotti M; Gordon LJ; Hill M; Zucchelli V; Watson JM; Zonzini L
Bioorg Med Chem Lett; 2009 Apr; 19(8):2338-42. PubMed ID: 19286377
[TBL] [Abstract][Full Text] [Related]
3. Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors.
Bueno AB; Gilmore J; Boot J; Broadmore R; Cooper J; Findlay J; Hayhurst L; Marcos A; Montero C; Mitchell S; Timms G; Tomlinson R; Wallace L; Walton L
Bioorg Med Chem Lett; 2007 Jun; 17(12):3344-8. PubMed ID: 17434731
[TBL] [Abstract][Full Text] [Related]
4. Novel 5-HT(1A/1B/1D) receptors antagonists with potent 5-HT reuptake inhibitory activity.
Serafinowska HT; Blaney FE; Lovell PJ; Merlo GG; Scott CM; Smith PW; Starr KR; Watson JM
Bioorg Med Chem Lett; 2008 Oct; 18(20):5581-5. PubMed ID: 18829312
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.
Zhou D; Stack GP; Lo J; Failli AA; Evrard DA; Harrison BL; Hatzenbuhler NT; Tran M; Croce S; Yi S; Golembieski J; Hornby GA; Lai M; Lin Q; Schechter LE; Smith DL; Shilling AD; Huselton C; Mitchell P; Beyer CE; Andree TH
J Med Chem; 2009 Aug; 52(15):4955-9. PubMed ID: 19719241
[TBL] [Abstract][Full Text] [Related]
6. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
Martínez-Esparza J; Oficialdegui AM; Pérez-Silanes S; Heras B; Orús L; Palop JA; Lasheras B; Roca J; Mourelle M; Bosch A; Del Castillo JC; Tordera R; Del Río J; Monge A
J Med Chem; 2001 Feb; 44(3):418-28. PubMed ID: 11462981
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
[TBL] [Abstract][Full Text] [Related]
8. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
Lovell PJ; Blaney FE; Goodacre CJ; Scott CM; Smith PW; Starr KR; Thewlis KM; Vong AK; Ward SE; Watson JM
Bioorg Med Chem Lett; 2007 Feb; 17(4):1033-6. PubMed ID: 17129726
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors.
Orús L; Pérez-Silanes S; Oficialdegui AM; Martínez-Esparza J; Del Castillo JC; Mourelle M; Langer T; Guccione S; Donzella G; Krovat EM; Poptodorov K; Lasheras B; Ballaz S; Hervías I; Tordera R; Del Río J; Monge A
J Med Chem; 2002 Sep; 45(19):4128-39. PubMed ID: 12213056
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.
Ward SE; Harrington FP; Gordon LJ; Hopley SC; Scott CM; Watson JM
J Med Chem; 2005 May; 48(10):3478-80. PubMed ID: 15887956
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism.
Oficialdegui AM; Martinez J; Pérez S; Heras B; Irurzun M; Palop JA; Tordera R; Lasheras B; del Río J; Monge A
Farmaco; 2000 May; 55(5):345-53. PubMed ID: 10983279
[TBL] [Abstract][Full Text] [Related]
13. Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives.
Torrado A; Lamas C; Agejas J; Jiménez A; Diaz N; Gilmore J; Boot J; Findlay J; Hayhurst L; Wallace L; Broadmore R; Tomlinson R
Bioorg Med Chem; 2004 Oct; 12(20):5277-95. PubMed ID: 15388156
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT
Gu ZS; Zhou AN; Xiao Y; Zhang QW; Li JQ
Eur J Med Chem; 2018 Jan; 144():701-715. PubMed ID: 29291438
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
Heinrich T; Böttcher H; Gericke R; Bartoszyk GD; Anzali S; Seyfried CA; Greiner HE; Van Amsterdam C
J Med Chem; 2004 Sep; 47(19):4684-92. PubMed ID: 15341484
[TBL] [Abstract][Full Text] [Related]
16. Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test.
Tatarczyńska E; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E
Eur J Pharmacol; 2004 Mar; 487(1-3):133-42. PubMed ID: 15033385
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship studies of CNS agents. Part 38. Novel 1,4-benzoxazin-3(4H)-one, 1,2-benzoxazolin-3-one and 1,3-benzoxazolin-2,4-dione arylpiperazine derivatives with different 5-HT1A and antagonistic 5-HT2A activities.
Mokrosz MJ; Kowalski P; Kowalska T; Majka Z; Duszyńska B; Bojarski AJ; Fruziński A; Karolak-Wojciechowska J; Wesołowska A; Kłodzińska A; Tatarczyńska E; Chojnacka-Wójcik E
Arch Pharm (Weinheim); 1999 Nov; 332(11):373-9. PubMed ID: 10605377
[TBL] [Abstract][Full Text] [Related]
18. Studies toward the discovery of the next generation of antidepressants. Part 2: incorporating a 5-HT(1A) antagonist component into a class of serotonin reuptake inhibitors.
Mewshaw RE; Meagher KL; Zhou P; Zhou D; Shi X; Scerni R; Smith D; Schechter LE; Andree TH
Bioorg Med Chem Lett; 2002 Feb; 12(3):307-10. PubMed ID: 11814784
[TBL] [Abstract][Full Text] [Related]
19. New 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propane derivatives with dual action at 5-HT1A serotonin receptors and serotonin transporter as a new class of antidepressants.
Martínez J; Pérez S; Oficialdegui AM; Heras B; Orús L; Villanueva H; Palop JA; Roca J; Mourelle M; Bosch A; Del Castillo JC; Lasheras B; Tordera R; del Río J; Monge A
Eur J Med Chem; 2001 Jan; 36(1):55-61. PubMed ID: 11231049
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.
Atkinson PJ; Bromidge SM; Duxon MS; Gaster LM; Hadley MS; Hammond B; Johnson CN; Middlemiss DN; North SE; Price GW; Rami HK; Riley GJ; Scott CM; Shaw TE; Starr KR; Stemp G; Thewlis KM; Thomas DR; Thompson M; Vong AK; Watson JM
Bioorg Med Chem Lett; 2005 Feb; 15(3):737-41. PubMed ID: 15664848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
